Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2025-12-31

172

Participants Needed

1

Research Sites

70 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

CONDITIONS

Official Title

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).

  2. Male or female subjects aged ≥ 18 years and ≤ 70 years

  3. A history of plaque psoriasis for ≥6 months at baseline

  4. Meet the following three criteria:

    1. Psoriasis Area and Severity Index (PASI) score ≥12
    2. Static Physician's Global Assessment (sPGA) score ≥3
    3. Psoriasis affected Body Surface Area (BSA) ≥10%
  5. The subject requires systemic treatment and/or phototherapy.

Not Eligible

You will not qualify if you...

  1. Diagnosed with non-plaque psoriasis.
  2. Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
  3. Presence of clinically serious, progressive, or uncontrolled disease.
  4. Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
  5. Pregnant or lactating women.
  6. The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China, 200443

Actively Recruiting

Loading map...

Research Team

M

Molly Lin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | DecenTrialz